• Explore /
  • Poster
  • / Cost-effectiveness of pembrolizumab as first-line treatment of locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States.

Cost-effectiveness of pembrolizumab as first-line treatment of locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States.

Abstract Poster

Authors

null

Yizhen Lai

Merck & Co., Inc., Kenilworth, NJ

Yizhen Lai, Yichen Zhong, Haojie Li, Karl Patterson, Oliver Hale, Yang Meng, Tara L. Frenkl, James Luke Godwin, Ronac Mamtani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cost, Value, and Policy; Health Equity and Disparities

Track

Cost, Value, and Policy,Health Care Access, Equity, and Disparities

Sub Track

Value/Cost of Care

Citation

J Clin Oncol 37, 2019 (suppl 27; abstr 93)

DOI

10.1200/JCO.2019.37.27_suppl.93

Abstract #

93

Poster Bd #

G8

Abstract Disclosures

Similar Posters

First Author: Sergio Bracarda

First Author: Lorenzo Antonuzzo

First Author: Guru P. Sonpavde

First Author: Terence W. Friedlander